The Novo Nordisk share $NOVO B (-1,98 %) rose by 2.3 % on Friday morning, once again securing the title of Europe's most valuable company 🏆 - ahead of $SAP (+0,86 %) whose shares fell by 2.2 % 📉.
📊 After a prolonged period of weakness, Novo Nordisk is now stable again - and could see a close exchange of favorites with SAP in the coming weeks 🔁.
🧪 Positive news from the previous evening provided a boost:
👉 The active ingredient amycretin, to regulate obesity, is entering the advanced testing phases after the approval authorities gave the green light ✅.
💼 There was also a tailwind from a report in the Financial Times:
Hedge fund Parvus Asset Management has bought into Novo and wants to have a say in the new CEO 💬.
➡️ The markets are reacting optimistically - remains exciting! 🔍📊
Source:
